B2B
Mendus
Stockholm, Swedenmendus.com/
Mendus is a clinical-stage biotechnology company developing immunotherapies to reduce tumor recurrence by harnessing the immune system to target residual cancer cells, with its lead product vididencel
aliveseries-c-plus
series-c-plus
Stage
1
Funding Rounds
About
Mendus is a clinical-stage biotechnology company developing immunotherapies to reduce tumor recurrence by harnessing the immune system to target residual cancer cells, with its lead product vididencel currently in clinical development.
Explore Mendus's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.